Zheng Quan Zhi Xing·2025-08-21 16:47Core Viewpoint - The company, Zhejiang Huakang Pharmaceutical Co., Ltd., has decided to terminate certain fundraising investment projects and permanently supplement the remaining funds into working capital, along with the cancellation of the fundraising special account [2][12]. Fundraising Basic Situation - The company raised a total of RMB 150,449.82 million from its initial public offering, with a net amount of RMB 137,477.15 million after deducting issuance costs of RMB 12,972.67 million [2][3]. Overview of Fundraising Investment Projects - The company has made several changes to its fundraising investment projects, including the termination of the "Viscose Fiber Press Liquid Comprehensive Utilization Industrialization Project" and reallocating funds to the "Annual Production of 30,000 Tons of High-Purity Crystalline Erythritol Construction Project" [3][4]. - The remaining unallocated funds of RMB 2,528.75 million were to be managed in a special fundraising account [3]. Project Termination and Adjustments - In 2024, the company decided to terminate the "Functional Sugar Alcohol Technology R&D Center Construction Project" and reallocate the remaining funds of RMB 12,963.95 million to working capital [5][8]. - The company adjusted the internal investment structure of the R&D center project, increasing construction investment by RMB 2,000.00 million and reducing equipment investment by the same amount [5][8]. Remaining Fund Usage Plan - The remaining funds after project termination will be permanently supplemented into working capital to enhance operational efficiency and maximize shareholder value [11][12]. Approval Procedures - The company has followed necessary internal approval procedures for the termination of fundraising investment projects and the reallocation of funds, ensuring compliance with relevant regulations [12][14].